Company intelligence / Profile preview
Promontory Therapeutics
New York, New York, United Statespromontorytx.com ↗
- Ownership
- Private
- Employees
- ~21
- Development stage
- Other
01
Overview
PT-112, the company's lead agent, is currently in Phase 2 clinical development for multiple cancer indications. It has demonstrated single-agent anti-cancer activity and an attractive tolerability profile across three Phase 1 studies.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule immunotherapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Beyond the preview
Go deeper on Promontory Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Promontory Therapeutics.